Pembrolizumab plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
- Salma K. Jabbour
- , Ki Hyeong Lee
- , Nikolaj Frost
- , Valeriy Breder
- , Dariusz M. Kowalski
- , Theodore Pollock
- , Evgeny Levchenko
- , Noemi Reguart
- , Alex Martinez-Marti
- , Baerin Houghton
- , Jean Baptiste Paoli
- , Sufia Safina
- , Keunchil Park
- , Takefumi Komiya
- , Amy Sanford
- , Vishal Boolell
- , Hong Liu
- , Ayman Samkari
- , Steven M. Keller
- , Martin Reck
- Rutgers Cancer Institute of New Jersey
- Chungbuk National University
- Berlin Institute of Health (BIH) and Charité - Universitätsmedizin Berlin
- N N Blokhin Russian Cancer Research Centre
- Maria Sklodowska-Curie Institute of Oncology
- Northeastern Health System
- N.N. Petrov National Medical Research Center of Oncology
- Hospital Clinic Barcelona
- Vall d'Hebron Institute of Oncology
- Port Macquarie Base Hospital
- Radiotherapie
- Medical Oncology
- Parkview Cancer Institute
- Sanford Health
- Ballarat Health Services
- Merck
- German Center of Lung Research
Research output: Contribution to journal › Article › peer-review
244
Link opens in a new tab
Scopus
citations